Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

P-075

Supelco

Primidone solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing

Select a Size

1 ML
$73.30

$73.30


Estimated to ship onMay 03, 2025


Request a Bulk Order

Select a Size

Change View
1 ML
$73.30

About This Item

Empirical Formula (Hill Notation):
C12H14N2O2
CAS Number:
Molecular Weight:
218.25
EC Number:
UNSPSC Code:
41116107
NACRES:
NA.24

$73.30


Estimated to ship onMay 03, 2025


Request a Bulk Order

grade

certified reference material

Quality Level

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

−20°C

SMILES string

CCC1(C(=O)NCNC1=O)c2ccccc2

InChI

1S/C12H14N2O2/c1-2-12(9-6-4-3-5-7-9)10(15)13-8-14-11(12)16/h3-7H,2,8H2,1H3,(H,13,15)(H,14,16)

InChI key

DQMZLTXERSFNPB-UHFFFAOYSA-N

General description

Primidone, marketed as the barbiturate Mysoline®, Prysoline, or Liskantin®, is an anticonvulsant used in the treatment of partial and generalized seizures. This Certified Spiking Solution® is suitable for use in LC/MS or GC/MS applications in clinical toxicology or therapeutic drug monitoring to ensure patients remain within the drug′s therapeutic range.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Liskantin is a registered trademark of Desitin Arzneimittel GmbH
Mysoline is a registered trademark of Valeant Pharmaceuticals North America LLC
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

Storage Class

3 - Flammable liquids

wgk_germany

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Feng Chen et al.
Environmental pollution (Barking, Essex : 1987), 159(6), 1490-1498 (2011-04-12)
This study investigated the occurrence of 43 emerging contaminants including 9 endocrine-disrupting chemicals and 34 pharmaceuticals in three sites in Hebei Province, north China. Each site has a wastewater irrigated plot and a separate groundwater irrigated plot for comparison purpose.
B Rezaei et al.
Talanta, 79(3), 669-675 (2009-07-07)
Application of electrospray ionization ion mobility spectrometry (ESI-IMS) as the detection technique for separation method based on molecular imprinted polymer (MIP) was investigated and evaluated. The method is exhaustively validated, including sensitivity, selectivity, recovery, reproducibility, and column capacity. The linear
Christopher G Favilla et al.
Parkinsonism & related disorders, 19(2), 171-175 (2012-10-16)
Many essential tremor patients continue to require tremor suppressing medications following deep brain stimulation. The true incidence of medication usage in the years following surgery remains unclear, and the use of medications has not been included in the post-operative analyses
Günther Deuschl et al.
The Lancet. Neurology, 10(2), 148-161 (2011-01-25)
Essential tremor is a common movement disorder. Tremor severity and handicap vary widely, but most patients with essential tremor do not receive a diagnosis and hence are never treated. Furthermore, many patients abandon treatment because of side-effects or poor efficacy.
Bradley N Gaynes et al.
Psychiatric services (Washington, D.C.), 60(11), 1439-1445 (2009-11-03)
The authors provide an overview of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study (www.star-d.org), a large-scale practical clinical trial to determine which of several treatments are the most effective "next-steps" for patients with major depressive disorder whose symptoms

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service